Efficacy of injectable platelet-rich fibrin and concentrated platelet-rich fibrin injections combined with arthrocentesis in the management of temporomandibular joint internal disorders: Randomized clinical trial.

This study aims to explore the effectiveness of injectable platelet-rich fibrin (I-PRF) and concentrated platelet-rich fibrin (C-PRF) in temporomandibular joint (TMJ) internal derangements. Patients with TMJ complaints were randomly divided into three groups in which arthrocentesis alone, arthrocentesis and I-PRF injections, or arthrocentesis and C-PRF injections were applied. Pain levels, maximum mouth opening (MMO), TMJ movements, and sounds were recorded preoperatively, postoperatively, at the 1st week, 1st month, and 3rd month; Oral health-related quality of life (OHRQoL) and mandibular dysfunction were evaluated preoperatively and at 3 months. 30 patients (mean age 41 ± 12.19) were included. Although I-PRF and C-PRF groups were found more effective clinically, no statistically significant differences were observed between the groups regarding pain level, MMO, and TMJ movements except for differences at postoperative-1st week (p = 0.023) for MMO and preoperative-1st month (p = 0.043), preoperative-3rd month (p = 0.005) and 1st week-3rd month (p = 0.007) for left lateral movement. No statistically significant differences were observed between the groups in terms of the Oral Health Impact Scale-14 (OHIP-14) and Mandibular Function Impairment Questionnaire (MFIQ) (p > 0.05). Although not significant, slightly improved values in the I-PRF group for pain and in the C-PRF group during the acute phase for pain and MMO suggest that I-PRF and, during the acute phase, C-PRF may be preferred after arthrocentesis to enhance clinical outcomes. However, these results still require more research on larger samples to be validated.